These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 797502)

  • 1. Clinical pharmacokinetics of levodopa in parkinson's disease.
    Bianchine JR; Shaw GM
    Clin Pharmacokinet; 1976; 1(5):313-38. PubMed ID: 797502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics of intravenous and oral levodopa in patients with Parkinson's disease who exhibit on-off fluctuations.
    Hardie RJ; Malcolm SL; Lees AJ; Stern GM; Allen JG
    Br J Clin Pharmacol; 1986 Oct; 22(4):429-36. PubMed ID: 3533125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal relationships between plasma and cerebrospinal fluid pharmacokinetics of levodopa and clinical effect in Parkinson's disease.
    Olanow CW; Gauger LL; Cedarbaum JM
    Ann Neurol; 1991 May; 29(5):556-9. PubMed ID: 1859185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

  • 5. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
    Extein I; Van Woert M; Roth RH; Bowers MB
    Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-dopa therapy combined with peripheral decarboxylase inhibitor (MK-486) in Parkinsonism.
    Ohmoto T; Kishikawa H
    Folia Psychiatr Neurol Jpn; 1975; 29(1):1-12. PubMed ID: 1158313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Senile Parkinsonism and dopa pharmacokinetics.
    Broe GA; Evans MA; Triggs EJ
    Clin Exp Neurol; 1981; 18():174-9. PubMed ID: 6926387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Abnormal movements of patients with Parkinsonism treated with L-dopa and anomalies of dopamine metabolism].
    Lhermitte F; Rosa A; Comoy E
    Rev Neurol (Paris); 1977 Jan; 133(1):3-11. PubMed ID: 847319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric emptying rate and the systemic availability of levodopa in the elderly parkinsonian patient.
    Evans MA; Broe GA; Triggs EJ; Cheung M; Creasey H; Paull PD
    Neurology; 1981 Oct; 31(10):1288-94. PubMed ID: 7202139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Putterman DB; Munhall AC; Kozell LB; Belknap JK; Johnson SW
    J Pharmacol Exp Ther; 2007 Oct; 323(1):277-84. PubMed ID: 17660384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor.
    Rinne UK; Sonninen V; Siirtola T
    Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542
    [No Abstract]   [Full Text] [Related]  

  • 14. Levodopa-induced dyskinesia in Parkinson's disease.
    Brotchie JM; Lee J; Venderova K
    J Neural Transm (Vienna); 2005 Mar; 112(3):359-91. PubMed ID: 15614429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis of dyskinesias in Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Fabbrini G; Juncos JL; Chase TN
    Ann Neurol; 1989 May; 25(5):523-6. PubMed ID: 2774496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug-induced dyskinesia during the treatment of Parkinson disease--biochemical studies].
    Friedman A
    Neurol Neurochir Pol; 1985; 19(5):401-3. PubMed ID: 2421191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramipexole has ameliorating effects on levodopa-induced abnormal dopamine turnover in parkinsonian striatum and quenching effects on dopamine-semiquinone generated in vitro.
    Asanuma M; Miyazaki I; Diaz-Corrales FJ; Shimizu M; Tanaka K; Ogawa N
    Neurol Res; 2005 Jul; 27(5):533-9. PubMed ID: 15978181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid.
    Nishi K; Kondo T; Narabayashi H; Takubo H; Muramoto S; Araki H
    J Neurol Sci; 1989 Aug; 92(1):65-70. PubMed ID: 2475587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.